



J&JPRD Media Contact:

Ernie Knewitz, Media

908-927-2953

Results From Phase III Study of Rivaroxaban Published in *The Lancet*

Raritan, NJ (June 25, 2008) -- Data published today in *The Lancet* demonstrated that extended duration treatment with the oral, once-daily, investigational anticoagulant rivaroxaban substantially reduced the number of venous blood clots in patients undergoing total hip replacement surgery compared with short-duration enoxaparin followed by placebo. The full article can be accessed through the following link www.thelancet.com.

Results of this trial, known as RECORD2, were previously presented at the annual meeting of the American Society of Hematology in December 2007.

Rivaroxaban is being jointly developed by Bayer HealthCare AG and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a wholly-owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at <http://www.jnjpharmarnd.com>.

###